BBOT (BridgeBio Oncology Therapeutics) Scaled Net Operating Assets: 0.27 (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics Scaled Net Operating Assets?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 Scaled Net Operating Assets is 0.27 as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BridgeBio Oncology Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $165.37 Mil. BridgeBio Oncology Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $42.72 Mil. BridgeBio Oncology Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $448.38 Mil. Therefore, BridgeBio Oncology Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.27.

BridgeBio Oncology Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Scaled Net Operating Assets Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Scaled Net Operating Assets
-19.50 -56.26 -0.07

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.03 -2.38 -0.12 -0.02 0.27

BBOT vs FTH, MNPR, MDXG: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Oncology Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's Scaled Net Operating Assets falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BridgeBio Oncology Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(22.921-34.519)/164.301
=-0.07

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=448.381 - 425.46
=22.921

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=37.285 - 2.244 - 0.522
=34.519

BridgeBio Oncology Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(165.371-42.722)/448.381
=0.27

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=417.646 - 252.275
=165.371

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=45.366 - 2.106 - 0.538
=42.722

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.27 mean?
BridgeBio Oncology Therapeutics (BBOT) has a Scaled Net Operating Assets of 0.27 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Scaled Net Operating Assets too high?
BridgeBio Oncology Therapeutics' current Scaled Net Operating Assets is 0.27. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Scaled Net Operating Assets compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Scaled Net Operating Assets of 0.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Scaled Net Operating Assets is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Scaled Net Operating Assets of 0.27. The current Scaled Net Operating Assets is 0.27. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Scaled Net Operating Assets is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price